E. Deindl and C. Kupatt (eds.), Therapeutic Neovascularization — Quo Vadis?, 1-22. © 2007 Springer.

Within the last two centuries, the development of and progress in modern cardiovascular drug therapies and mechanical revascularization with balloon angioplasty and coronary artery by-pass surgery has improved the prognosis for patients with both acute and chronic myocardial ischemia. However, there is still a large amount of patients with severe coronary artery disease, which cannot be treated satisfactorily with conventional therapies. This has lead to an extensive research to find new treatment modalities. The intensive research within the field of molecular biology has discovered several families of proteins with an angiogenic potential [1]. However, only a few of these vascular growth factors have moved from preclinical animal studies into clinical trials. The vascular endothelial growth factors and the fibroblast growth factors both have the potential to induce therapeutic angiogenesis, i.e. growth of new vessels, in human myocardium and they have both been tested in patients with coronary artery disease.

This review focus on the results obtained by clinical therapeutic angiogenesis with vascular growth factors and the perspective for this treatment in the future in patients with severe ischemic coronary artery disease.

Was this article helpful?

0 0

Post a comment